Volume 44, Issue 6 pp. 976-980
Brief Communication
Full Access

Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy

Jose Luis Molinuevo MD

Jose Luis Molinuevo MD

Service of Neurology, Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona

Search for more papers by this author
Francesc Graus MD

Corresponding Author

Francesc Graus MD

Service of Neurology, Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona

Service of Neurology, Hospital Clínic, Villarroel 170, Barcelona 08036, SpainSearch for more papers by this author
Carmen Serrano MD

Carmen Serrano MD

Service of Neurology, Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona;Spain

Search for more papers by this author
Ramón Reñe MD

Ramón Reñe MD

Service of Neurology, CSU Bellvitge, Universitat de Barcelona, Barcelona

Search for more papers by this author
Antonio Guerrero MD

Antonio Guerrero MD

Service of Neurology, Hospital Universitario San Carlos, Madrid, Spain

Search for more papers by this author
Isabel Illa MD

Isabel Illa MD

Service of Neurology, Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona;Spain

Search for more papers by this author
First published: 08 October 2004
Citations: 129

Abstract

Anti-Hu antibodies (Hu-Abs) were positive in 40 patients with paraneoplastic sensory neuropathy (PSN) and in 1 patient with idiopathic sensory neuropathy in a series of 126 patients who presented with clinical features suggestive of PSN. The specificity of Hu-Abs was 99% and the sensitivity was 82%. Nine (18%) PSN patients were Hu-Ab–negative, and their sera did not harbor other specific anti-neuronal of anti-ganglioside antibodies. Small cell lung carcinoma (SCLC) was the leading neoplasm in the Hu-Ab–positive (79%) and Hu-Ab–negative (44%) groups. This study confirms the value of Hu-Abs for the diagnosis of PSN and SCLC and also emphasizes that in patients with possible PSN, the absence of Hu-Abs does not exclude cancer, particularly in those patients with risk factors for SCLC.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.

click me